POMS

Executive Summary

POMS Corporation is a leading provider of Manufacturing Execution System (MES) software tailored for highly regulated life science industries, including pharmaceuticals, biotech, and medical devices. Founded in 2000 and headquartered in Arlington, USA, the company's flagship product, POMSnet Aquila, is a fully web-based, cloud-ready platform that enables FDA-compliant electronic batch records, streamlining production, ensuring compliance, and accelerating batch release. With over two decades of domain expertise, POMS occupies a niche but critical position in the digital transformation of life sciences manufacturing, where regulatory rigor and quality control are paramount. The company faces competition from larger industrial automation players but differentiates through deep industry specialization and a proven track record in validated environments. As the pharmaceutical industry increasingly adopts Industry 4.0 and regulators push for digital recordkeeping, POMS is well-positioned to benefit from tailwinds such as the rise of cell and gene therapies, which require sophisticated MES for complex, personalized production. However, the company operates as a private entity with limited public financial disclosures, making it challenging to assess performance. Key risks include the need for continuous innovation to keep pace with cloud and AI advancements, as well as potential consolidation in the MES market. Overall, POMS represents a compelling but high-risk opportunity in a specialized segment of digital health and manufacturing technology.

Upcoming Catalysts (preview)

• Q3 2026FDA final guidance on electronic batch records and data integrity75% success
• TBDMajor customer win or strategic partnership with a top 10 pharma company50% success
• Q4 2026Expansion of POMSnet Aquila capabilities for cell and gene therapy manufacturing60% success